Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Syros Pharmaceuticals, Inc. | syrs-ex322_11.htm |
| EX-32.1 - EX-32.1 - Syros Pharmaceuticals, Inc. | syrs-ex321_9.htm |
| EX-31.2 - EX-31.2 - Syros Pharmaceuticals, Inc. | syrs-ex312_10.htm |
| EX-31.1 - EX-31.1 - Syros Pharmaceuticals, Inc. | syrs-ex311_6.htm |
| EX-4.1 - EX-4.1 - Syros Pharmaceuticals, Inc. | syrs-ex41_226.htm |
| 10-K - 10-K - Syros Pharmaceuticals, Inc. | syrs-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
1. |
Registration Statement (Form S-8 No. 333-212363) pertaining to the 2012 Equity Incentive Plan, 2016 Stock Incentive Plan, and 2016 Employee Stock Purchase Plan of Syros Pharmaceuticals, Inc., |
|
|
2. |
Registration Statements (Form S-8 Nos. 333-216821, 333-223574, 333-230116 and 333-236895) pertaining to the 2016 Stock Incentive Plan and 2016 Employee Stock Purchase Plan of Syros Pharmaceuticals, Inc., |
|
|
3. |
Registration Statement (Form S-3 No. 333-222634) of Syros Pharmaceuticals, Inc., |
|
|
4. |
Registration Statement (Form S-3 No. 333-239141) of Syros Pharmaceuticals, Inc., and |
|
|
5. |
Registration Statement (Form S-3 No. 333-251941) of Syros Pharmaceuticals, Inc. |
of our report dated March 4, 2021, with respect to the consolidated financial statements of Syros Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 4, 2021